WO2006037247A1 - Type i interferon blocking agents for prevention and treatment of psoriasis - Google Patents

Type i interferon blocking agents for prevention and treatment of psoriasis Download PDF

Info

Publication number
WO2006037247A1
WO2006037247A1 PCT/CH2005/000566 CH2005000566W WO2006037247A1 WO 2006037247 A1 WO2006037247 A1 WO 2006037247A1 CH 2005000566 W CH2005000566 W CH 2005000566W WO 2006037247 A1 WO2006037247 A1 WO 2006037247A1
Authority
WO
WIPO (PCT)
Prior art keywords
ifn
type
psoriasis
interferon
antibody
Prior art date
Application number
PCT/CH2005/000566
Other languages
French (fr)
Inventor
Michel Gilliet
Frank O. Nestle
Original Assignee
Universität Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Zürich filed Critical Universität Zürich
Priority to AU2005291741A priority Critical patent/AU2005291741B2/en
Priority to CA002582471A priority patent/CA2582471A1/en
Priority to JP2007534986A priority patent/JP2008515819A/en
Priority to MX2007003809A priority patent/MX2007003809A/en
Priority to BRPI0516470-2A priority patent/BRPI0516470A/en
Priority to NZ554065A priority patent/NZ554065A/en
Priority to EP05786466A priority patent/EP1796722A1/en
Priority to US11/664,869 priority patent/US20090155286A1/en
Publication of WO2006037247A1 publication Critical patent/WO2006037247A1/en
Priority to IL182087A priority patent/IL182087A0/en
Priority to NO20072024A priority patent/NO20072024L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • Type I interferon blocking agents for prevention and treatment of psoriasis
  • the invention relates to the use of a type I interferon blocking agent for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.
  • Psoriasis is a common autoimmune-related inflammatory disease affecting the human skin.
  • psoriasis formation results from an overt self-perpetuating activation of autoreactive IFN- ⁇ secreting T cells.
  • the initial onset of skin lesions is followed by chronic relapses of the disease, typically triggered by environmental factors including infections, mechanical stress and drugs. It has been proposed that these insults may drive the pathogenic T cell cascade through a yet unidentified innate immune response.
  • Plasmacytoid dendritic cell precursors are key effectors in innate antiviral immunity due to their unique ability to secrete large amounts of type I interferons (IFN- ⁇ / ⁇ ) in response to viral stimulation.
  • Virally exposed PDC subsequently differentiate into T cell stimulatory dendritic cells (DC) themselves or induce maturation of bystander myeloid DC through IFN- ⁇ , thus providing a unique link between innate and adaptive anti-viral immunity.
  • DC T cell stimulatory dendritic cells
  • IFN- ⁇ type I interferons
  • PDC may also accumulate in peripheral tissues of certain non ⁇ infectious inflammatory disorders such as allergic contact dermatitis, cutaneous lupus erythematosus and psoriasis, however a functional relevance for PDC or their secreted products such as type I IFNs has not been addressed or proven so far.
  • Type I (IFN- ⁇ , IFN- ⁇ , IFN- ⁇ ) IFNs are members of a cytokine family including several structurally related IFN- ⁇ proteins and a single IFN- ⁇ protein binding to the type I IFN surface receptor. Type I IFNs inhibit viral replication, increase the lytic potential of NK cells, increase expression of class I MHC molecules and stimulate the development of T helper 1 cells in humans.
  • Van der Fits et al. [J Invest Dermatol 2004, 122: 51-60] describe an activated type I interferon signalling pathway in psoriatic lesional skin, but do not suggest that blocking of this pathway could be used for prevention or therapy of psoriasis.
  • Single case reports have indicated that systemic IFN- ⁇ given during adjuvant therapy of melanoma or hepatitis therapy can occasionally trigger psoriasis in predisposed individuals [Pauluzzi et al., Acta Derm Venereol 1993, 73: 395; Funk et al., Br J Dermatol 1991 , 125: 463-5].
  • IFN- ⁇ is just thought of being one of many factors able to induce psoriasis.
  • Other factors such as physical and psychological stress, HIV infection as well as various medications including lithium, beta blockers and anti-malarial drugs are also well-known triggers of psoriasis.
  • Therapeutic IFN- ⁇ doses, added through the exogenous route, might be a non- specific trigger of several possible downstream psoriasis inducing factors.
  • WO 00/64936 [Wieser] describes peptide homodimers and peptide heterodimers binding to the IFN- ⁇ 2 receptor and focuses on the physical and biochemical activities of these compounds representing IFN- ⁇ 2 substitutes. Application of these compounds to inflammatory and neoplastic diseases in the broadest sense are suggested, and the list of diseases also contains psoriasis. However, there is no indication that IFN- ⁇ 2 antagonists should be used.
  • the invention relates to the use of a type I interferon blocking agent, such as a type I IFN antagonist or type I IFN-receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.
  • a type I interferon blocking agent such as a type I IFN antagonist or type I IFN-receptor antagonist
  • the invention relates to such a use, wherein the type I IFN antagonist is an IFN- ⁇ antagonist, for example an anti-IFN- ⁇ antibody or antibody fragment, preferably a humanized antibody, a type I IFN receptor fusion protein, or also short interfering (si) RNA or antisense oligonucleotides inhibiting IFN- ⁇ production by sequence-specific targeting of IFN- ⁇ mRNA.
  • IFN- ⁇ antagonist for example an anti-IFN- ⁇ antibody or antibody fragment, preferably a humanized antibody, a type I IFN receptor fusion protein, or also short interfering (si) RNA or antisense oligonucleotides inhibiting IFN- ⁇ production by sequence-specific targeting of IFN- ⁇ mRNA.
  • Similar reagents antagonizing other type I IFN family members or groups of type I IFNs are also part of the invention.
  • the invention further relates to such a use, wherein the type I IFN-receptor antagonist is an anti-IFN- ⁇ / ⁇ -receptor antibody or antibody fragment, mutant type I IFN/Fc fusion protein or small molecule specifically interfering with type I IFN signalling.
  • the type I IFN-receptor antagonist is an anti-IFN- ⁇ / ⁇ -receptor antibody or antibody fragment, mutant type I IFN/Fc fusion protein or small molecule specifically interfering with type I IFN signalling.
  • IFN-a production is an early event during the development of psoriatic skin lesions and is principally mediated by dermal PDC.
  • IFN-a/ ⁇ signalling is crucial for local T cell expansion and the development of psoriasis.
  • Antagonizing type I IFNs (e.g. antagonizing IFN- ⁇ , while leaving IFN- ⁇ intact) provides the unique opportunity to specifically target the type I IFN mediated autoimmune disease process in psoriasis while potentially leaving an important IFN- ⁇ mediated antiviral immune response intact. Antagonizing IFN- ⁇ not only clears the disease, but also prevents relapse as is demonstrated in a relevant preclinical model.
  • the AGR psoriasis mouse model [Boyman et al., J Exp Med 2004, 199: 731-736] provides for the first time the platform to prove the effectiveness of type I IFN blocking in prevention and therapy of psoriasis. This clinically relevant psoriasis model supports that inhibiting type I IFN blocks development of psoriasis and is a potent way to prevent and treat psoriasis in humans.
  • IFN- ⁇ expression during the development of psoriatic lesions is studied in a xenotransplantation model, in which uninvolved skin of psoriatic patients transplanted onto AGR " ' ' mice spontaneously converts into a fully-fledged psoriatic skin lesion within 35 days.
  • AGR129 mice deficient in type I (A) and type Il (G) IFN receptor in addition to being RAG-/-, are kept pathogen-free throughout the study. Keratomes of uninvolved skin are transplanted to the back of mice using an absorbable tissue seal.
  • This humanized mouse model system is dependent on the local activation and proliferation of resident human T cells derived from the engrafted pre-psoriatic skin.
  • IFN- ⁇ expression is especially important during the early phase of the development of the psoriatic phenotype but has consequences for the whole disease process.
  • Intracellular IFN- ⁇ expression is confined to BDCA2+ cells (Fig. 1d), indicating that PDC represent the principal IFN- ⁇ producers in developing psoriatic skin lesions.
  • IFN- ⁇ expression is not detectable on PDC derived from uninvolved skin nor in peripheral blood of the same psoriasis patient. Since PDCs contain high amounts of type I interferons, PDC-derived IFN- ⁇ plays a crucial role in the elicitation of psoriasis.
  • Intravenous injection of neutralizing anti-IFN- ⁇ / ⁇ -receptor antibody inhibits the local activation and expansion of resident T cells (Fig. 2a), and completely blocks the development of the psoriatic phenotype, with a significant reduced papillomatosis (Fig. 2b) compared to mice receiving the isotype-matched control antibody.
  • Anti-BDCA2 antibody specifically targets human PDC and inhibits type I IFN-production by PDC in vitro.
  • Intravenous injection of anti-BDCA2 monoclonal antibody (mAb) leads to a 14-fold reduction of lesional IFN- ⁇ at day 13 after transplantation (Fig. 3a), inhibits the dermal T cell expansion (Fig. 3b) and the development of the psoriasis phenotype, quantified by epidermal papillomatosis (Fig. 3c) and acanthosis (Fig. 3d).
  • IFN- ⁇ Blockade of IFN- ⁇ blocks psoriasis while leaving IFN- ⁇ signalling intact for a potential antiviral immune response.
  • Blocking agents refer to any DNA, RNA (si RNA, antisense molecules), peptide, protein (including fusion protein), antibody or small molecules interfering with type I IFN signalling and function and/or type I IFN production by PDCs in inflammatory diseases.
  • blocking agents are (i) humanized or human anti-IFN- ⁇ whole antibodies or antibody fragments (Fab or scFv), antagonizing secreted IFN- ⁇ , (ii) short interfering (si) RNA or antisense oligonucleotides inhibiting IFN- ⁇ production, (iii) anti-IFN- ⁇ / ⁇ -receptor antibodies, mutant type I IFN/Fc fusion proteins, type I IFN receptor fusion proteins, or small molecules interfering with type I IFN signalling.
  • One aspect of the invention relates to a method of treating psoriasis comprising administering an anti-IFN- ⁇ antibody or antibody fragment in a quantity effective against psoriasis to a mammal in need thereof, for example to a human requiring such treatment.
  • the treatment may be for prophylactic or therapeutic purposes.
  • the anti-IFN- ⁇ antibody is preferably in the form of a pharmaceutical preparation comprising the anti-IFN- ⁇ antibody and optionally a pharmaceutically acceptable carrier and optionally adjuvants.
  • the anti-IFN- ⁇ antibody is used in an amount effective against psoriasis.
  • the dosage of the active ingredient depends upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, the mode of administration, and whether the administration is for prophylactic or therapeutic purposes.
  • the daily dose administered is from approximately 1 mg to approximately 500 mg, preferably from approximately 10 mg to approximately 100 mg, of an anti-IFN- ⁇ antibody.
  • Administering other blocking agents referred to above is also included in the invention, in particular administering pharmaceutical preparations comprising short interfering (si) RNA or antisense oligonucleotides inhibiting IFN- ⁇ production, or anti-IFN- ⁇ / ⁇ -receptor antibodies, mutant type I IFN/Fc fusion proteins, type I IFN receptor fusion proteins or small molecules interfering with type I IFN signalling.
  • pharmaceutical preparations comprising short interfering (si) RNA or antisense oligonucleotides inhibiting IFN- ⁇ production, or anti-IFN- ⁇ / ⁇ -receptor antibodies, mutant type I IFN/Fc fusion proteins, type I IFN receptor fusion proteins or small molecules interfering with type I IFN signalling.
  • These compounds are likewise used in an amount effective against psoriasis.
  • the dosage is chosen by the practitioner based on the particular compound to be administrated and the individual pharmacokinetic data, and also on the species, its age, weight, and individual
  • compositions for parenteral administration such as intravenous, intramuscular or subcutaneous administration, are especially preferred.
  • the pharmaceutical compositions comprise from approximately 1% to approximately 95% active ingredient, preferably from approximately 20% to approximately 90% active ingredient.
  • parenteral administration preference is given to the use of suspensions or dispersions of the anti-IFN- ⁇ antibody or other type I IFN blocking agent mentioned above, especially in isotonic aqueous solutions, which, for example, can be made up shortly before use.
  • compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-increasing agents, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known perse, for example by means of conventional dissolving and lyophilizing processes.
  • excipients for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-increasing agents, salts for regulating osmotic pressure and/or buffers.
  • An antibody useful in the invention is prepared by standard methods. Humanized antibodies and antibody fragments are obtained by recombinant technologies as previously described [reviewed by Dall'Acqua et al., Curr Op Struct Biol 1988, 8: 443-50]. Alternatively, entirely human antibodies can be obtained using either phage display technologies [reviewed by Winter et al., Annu Rev Immunol 1994, 12: 433-55] or transgenic "human" mice with partial human heavy and light chain loci inserted into their genomes [reviewed by Br ⁇ ggeman et al., Curr Op Biotechnol 1997, 8: 503-8]. Preparation of si RNA or antisense oligonucleotides likewise uses standard technology.
  • An anti-IFN- ⁇ antibody or other type I IFN blocking agent mentioned above can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations of a blocking agent of the invention and one or more other therapeutic agents known in the treatment of psoriasis, the administration being staggered or given independently of one another, or being in the form of a fixed combination.
  • Combination partners considered are topical corticosteroids, UV light, retinoids, methotrexate, other biologies targeting the altered immune system in psoriasis or derivatives of vitamin D3.
  • RNA from homogenized skin specimens is extracted and reverse transcribed as previously described [Boyman et al., J Exp Med 2004, 199: 731-736].
  • Complementary DNA is quantitatively analyzed for the expression of IFN- ⁇ and IRF-7 transcripts by real time PCR, using primers designed against most human IFN- ⁇ sequences (purchased from Applied Biosystems, Foster City, CA) and against human IRF-7 (left, TCCCCACGCTATACCATCTACCT-3'; right, ACAGCCAGGGTTCCAGCTT- 3'). 18S ribosomal RNA is used for normalisation.
  • IFN- ⁇ quantification is done by using a primer kit recognizing most human IFN- ⁇ genes and which does not recognize its mouse counterpart (purchased from Search-LC, Heidelberg, Germany).
  • Human GAPDH mRNA levels are quantified using human-specific primers (left, ATTGCCCTCAACGACCACTTTG-3'; right, TTGATGGTACATGAAAGGTGAGG-3') and used for normalization.
  • mice deficient in type I (A) and type Il (G) IFN receptors in addition to being RAG-2 " ' " , are kept pathogen free throughout the study. Keratomes of symptomless pre-psoriatic skin are transplanted to the back of mice using an absorbable tissue seal, as previously described [Boyman et al., loc. cit.]. 35 days after engraftment transplanted skin is removed and snap frozen for histological or mRNA expression analysis. CD3+ T cell counts, acanthosis and papillomatosis index are determined histologically as previously published [Boyman et al., loc. cit.]. CD3+ T cell values represent the mean cell count of three random fields assessed by a 400-fold magnification by two independent investigators. The indicated papillomatosis and acanthosis values represent the mean of 10 random areas of each sample.
  • IFN- ⁇ reconstitution experiments 30'0OO IU recombinant human IFN- ⁇ 2a (Roferon ® A, Roche Pharma AG 1 Reinach, Switzerland) are administered subcutaneously 3 times a week for 35 days. Dosage corresponds to the therapeutic dose of 8 Mio IU used in humans, and is deduced by an allometric approach as previously described [Boyman et al., loc. cit.].

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The discovery of plasmacytoid dendritic cell precursors (PDC) as crucial effector cells with high production of type I interferons (IFNs) in early psoriasis development has led to the present invention that blocking of type I IFNs can be used for prevention and therapy of psoriasis. The invention relates to the use of a type I interferon blocking agent, such as a type I IFN antagonist (e.g. an anti-IFN-α antibody) or type I IFN receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.

Description

Type I interferon blocking agents for prevention and treatment of psoriasis
Field of the invention
The invention relates to the use of a type I interferon blocking agent for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.
Background of the invention
Psoriasis is a common autoimmune-related inflammatory disease affecting the human skin. There is compelling evidence that, similarly to Crohn's disease and rheumatoid arthritis, psoriasis formation results from an overt self-perpetuating activation of autoreactive IFN-γ secreting T cells. The initial onset of skin lesions is followed by chronic relapses of the disease, typically triggered by environmental factors including infections, mechanical stress and drugs. It has been proposed that these insults may drive the pathogenic T cell cascade through a yet unidentified innate immune response.
Plasmacytoid dendritic cell precursors (PDC) are key effectors in innate antiviral immunity due to their unique ability to secrete large amounts of type I interferons (IFN-α/β) in response to viral stimulation. Virally exposed PDC subsequently differentiate into T cell stimulatory dendritic cells (DC) themselves or induce maturation of bystander myeloid DC through IFN-α, thus providing a unique link between innate and adaptive anti-viral immunity. During homeostasis, PDC are encountered exclusively in blood and lymphoid organs, however viral infection leads to active recruitment of PDC from the blood into peripheral sites of primary infection. Wollenberg et al. [J Invest Dermatol 2002, 119: 1096- 102] have shown that PDC may also accumulate in peripheral tissues of certain non¬ infectious inflammatory disorders such as allergic contact dermatitis, cutaneous lupus erythematosus and psoriasis, however a functional relevance for PDC or their secreted products such as type I IFNs has not been addressed or proven so far.
Type I (IFN-α, IFN-β, IFN-ω) IFNs are members of a cytokine family including several structurally related IFN-α proteins and a single IFN-β protein binding to the type I IFN surface receptor. Type I IFNs inhibit viral replication, increase the lytic potential of NK cells, increase expression of class I MHC molecules and stimulate the development of T helper 1 cells in humans.
In the past, there have been some reports in the literature dealing with the association between psoriasis and type I IFNs or the description of IFN-α blocking agents. Schmid et al. [J of IFN Res 1994, 14: 229-234] have detected low levels of IFN-α mRNA expression in psoriasis epidermis. However, they failed to show IFN-α expression on the protein level. Furthermore IFN-α was found only in the epidermal compartment. Although the authors provided direct evidence that the IFN-α system is locally activated in psoriasis they concluded that this might be the result of a viral infection or a dysregulation of the cytokine network.
Van der Fits et al. [J Invest Dermatol 2004, 122: 51-60] describe an activated type I interferon signalling pathway in psoriatic lesional skin, but do not suggest that blocking of this pathway could be used for prevention or therapy of psoriasis. Single case reports have indicated that systemic IFN-α given during adjuvant therapy of melanoma or hepatitis therapy can occasionally trigger psoriasis in predisposed individuals [Pauluzzi et al., Acta Derm Venereol 1993, 73: 395; Funk et al., Br J Dermatol 1991 , 125: 463-5]. However, this is a rare event considering the high prevalence of psoriasis and the frequent use of IFN-α in cancer patients as well as in anti-infectious therapy. Furthermore, IFN-α is just thought of being one of many factors able to induce psoriasis. Other factors such as physical and psychological stress, HIV infection as well as various medications including lithium, beta blockers and anti-malarial drugs are also well-known triggers of psoriasis. Therapeutic IFN-α doses, added through the exogenous route, might be a non- specific trigger of several possible downstream psoriasis inducing factors.
Chuntharapai et al. [Cytokine 2001 , 15: 250-260] focus on the development of a therapeutic agent that neutralizes IFN-α, i.e. the development of a humanized antibody. No experimental data are provided to show prevention or therapy in any of the known autoimmune diseases, although insulin-dependent diabetes mellitus (IDDM) or systemic lupus erythematosis (SLE) are mentioned as potential diseases to be treated. The paper questions the statement about an association between IFN-α and psoriasis or Crohn's disease by referring to the limited number of patients having been analyzed.
WO 00/64936 [Wieser] describes peptide homodimers and peptide heterodimers binding to the IFN-α 2 receptor and focuses on the physical and biochemical activities of these compounds representing IFN-α 2 substitutes. Application of these compounds to inflammatory and neoplastic diseases in the broadest sense are suggested, and the list of diseases also contains psoriasis. However, there is no indication that IFN-α 2 antagonists should be used.
There is an unmet need for novel psoriasis therapies since current therapies of psoriasis are limited by their limited efficacy, their side effects and their inability to prevent new relapses. While novel drugs such as anti-TNF-α targeted therapies are able to induce fast disease remission, long term therapy is not an option due to their high potential toxicity.
Summary of the invention
The invention relates to the use of a type I interferon blocking agent, such as a type I IFN antagonist or type I IFN-receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.
In particular, the invention relates to such a use, wherein the type I IFN antagonist is an IFN-α antagonist, for example an anti-IFN-α antibody or antibody fragment, preferably a humanized antibody, a type I IFN receptor fusion protein, or also short interfering (si) RNA or antisense oligonucleotides inhibiting IFN-α production by sequence-specific targeting of IFN-α mRNA. Similar reagents antagonizing other type I IFN family members or groups of type I IFNs are also part of the invention. The invention further relates to such a use, wherein the type I IFN-receptor antagonist is an anti-IFN-α/β-receptor antibody or antibody fragment, mutant type I IFN/Fc fusion protein or small molecule specifically interfering with type I IFN signalling.
Brief description of the figures
Figure 1. IFN-a production is an early event during the development of psoriatic skin lesions and is principally mediated by dermal PDC.
(a) Normalized IFN-α and IRF-7 mRNA expression in psoriatic plaque lesions (PP, n=24) and normal skin (NN1 n=11). The figures of the x axis (mRNA) represent relative mRNA expression. (b) lmmunohistochemistry for MxA protein on cryosections of psoriatic plaque lesions (PP, n=8), uninvolved skin of psoriatic patients (PN, n=4), normal skin of healthy individuals (NN, n=4) and atopic dermatitis skin (AD, n=4) specimen. Percentages of MxA-positive cells among the total dermal and epidermal cells are calculated from mean of two independent counts of three random fields with a 400-fold magnification. + = 0-25%, ++ = 25-50%, +++ = 50-75%, ++++ = 75-100%, < = below detection limit. (c) Lesional IFN-α expression during the spontaneous development of a psoriatic lesion from uninvolved skin transplanted onto AGR"'" mice. Kinetics of human IFN-α mRNA expression relative to human GAPDH mRNA (IFN-α mRNA, bars) in comparison to the expansion of resident CD3 T cells (CD3, solid line) and the induction of psoriatic papillomatosis (Pap, dashed line). d=days after transplantation. Data represent the mean +/- standard deviation (SD) of two independent experiments.
(d) Double staining of intracellular IFN-α and surface BDCA-2 in dermal single cell suspensions derived from developing psoriatic lesions (d-PP, advancing edges of a psoriatic plaques) and uninvolved skin (PN). Figures in the quadrants represent %.
Figure 2. IFN-a/β signalling is crucial for local T cell expansion and the development of psoriasis.
(a) Total CD3 T cell count and (b) epidermal papillomatosis (Pap) in skin grafts before transplantation (uninvolved skin day 0, PN) and 35 days post transplantation (p.t.) following the administration of isotype-matched control antibody (IgG) or an anti-IFN-α/β- receptor mAb (α-IFN-R), or in a psoriatic plaque (PP) of the graft donor. Error bars in (a) represent one standard deviation (SD). Dots in (b) represent independently grafted mice.
Figure 3. The development of psoriasis is dependent on type I IFN production by PDC.
(a) Total human IFN-α mRNA expression relative to human GAPDH mRNA in skin grafts harvested 13 days post transplantation (p.t.) following the administration of isotype-control
Ab (IgG) or anti-BDCA-2 mAb (α-BDCA-2).
(b) Total CD3 T cell count, (c) epidermal papillomatosis (Pap) and (d) acanthosis (Ac) in skin grafts before transplantation (uninvolved skin d 0, PN) and 35 days post transplantation (p.t.) following the administration of isotype-matched control Ab (IgG), anti- BDCA-2 mAb (α-BDCA-2), or anti-BDCA2 plus human recombinant IFN-α2 (α-BDCA-2 + IFN-α).
Detailed description of the invention
The discovery of PDC as crucial effector cells with high production of type I IFNs in early psoriasis development has led to the present invention that blocking of type I IFNs can be used as prevention and therapy of psoriasis. High numbers of PDC infiltrating the skin of both psoriatic plaque lesions as well as uninvolved (normal appearing) skin of psoriatic patients can be shown by immunohistochemistry and flow cytometry of single cell suspensions using an antibody specific for PDC (anti-BDCA-2). Interestingly, in contrast to the resting phenotype of PDC in uninvolved skin, PDC infiltrating psoriatic plaque lesions display an activated phenotype. PDC activation during the transition from uninvolved skin into psoriatic plaque lesions contributes to the pathogenesis of psoriasis.
Antagonizing type I IFNs (e.g. antagonizing IFN-α, while leaving IFN-β intact) provides the unique opportunity to specifically target the type I IFN mediated autoimmune disease process in psoriasis while potentially leaving an important IFN-β mediated antiviral immune response intact. Antagonizing IFN-α not only clears the disease, but also prevents relapse as is demonstrated in a relevant preclinical model. The AGR psoriasis mouse model [Boyman et al., J Exp Med 2004, 199: 731-736] provides for the first time the platform to prove the effectiveness of type I IFN blocking in prevention and therapy of psoriasis. This clinically relevant psoriasis model supports that inhibiting type I IFN blocks development of psoriasis and is a potent way to prevent and treat psoriasis in humans.
IFN-α expression during the development of psoriatic lesions is studied in a xenotransplantation model, in which uninvolved skin of psoriatic patients transplanted onto AGR"'' mice spontaneously converts into a fully-fledged psoriatic skin lesion within 35 days. AGR129 mice, deficient in type I (A) and type Il (G) IFN receptor in addition to being RAG-/-, are kept pathogen-free throughout the study. Keratomes of uninvolved skin are transplanted to the back of mice using an absorbable tissue seal. This humanized mouse model system is dependent on the local activation and proliferation of resident human T cells derived from the engrafted pre-psoriatic skin.
Initial screening of psoriatic plaque lesions does not show significant upregulation of IFN-α mRNA compared to normal skin of healthy donors. However, psoriatic plaque lesions but not uninvolved skin or normal skin demonstrate an IFN-α signature with significantly increased expression of IRF-7, an IFN-α inducible gene (Fig. 1a), and the presence of the IFN-α inducible MxA protein (Fig. 1 b), suggesting that IFN-α is produced earlier during the development of the psoriatic phenotype. Analysis of human IFN-α expression reveals increased mRNA levels as early as day 7 after engraftment, reaching a peak at day 14, before rapidly declining (Fig. 1c). The induction of IFN-α expression at day 7 and 14 is paralleled by the local expansion of resident T cells. In contrast, disease formation, quantified by epidermal papillomatosis, shows delayed kinetics, starting at day 21 after transplantation and reaching its full development at day 35 (Fig. 1c). These data indicate that IFN-α expression is especially important during the early phase of the development of the psoriatic phenotype but has consequences for the whole disease process.
Intracellular IFN-α expression is confined to BDCA2+ cells (Fig. 1d), indicating that PDC represent the principal IFN-α producers in developing psoriatic skin lesions. By contrast, IFN-α expression is not detectable on PDC derived from uninvolved skin nor in peripheral blood of the same psoriasis patient. Since PDCs contain high amounts of type I interferons, PDC-derived IFN-α plays a crucial role in the elicitation of psoriasis.
Intravenous injection of neutralizing anti-IFN-α/β-receptor antibody, starting immediately after transplantation, inhibits the local activation and expansion of resident T cells (Fig. 2a), and completely blocks the development of the psoriatic phenotype, with a significant reduced papillomatosis (Fig. 2b) compared to mice receiving the isotype-matched control antibody.
The spontaneous conversion of uninvolved pre-psoriatic skin to psoriasis in AGR"'" mice is mediated by PDC activation and the secretion of IFN-α. Anti-BDCA2 antibody specifically targets human PDC and inhibits type I IFN-production by PDC in vitro. Intravenous injection of anti-BDCA2 monoclonal antibody (mAb) leads to a 14-fold reduction of lesional IFN-α at day 13 after transplantation (Fig. 3a), inhibits the dermal T cell expansion (Fig. 3b) and the development of the psoriasis phenotype, quantified by epidermal papillomatosis (Fig. 3c) and acanthosis (Fig. 3d).
Addition of exogenous IFN-α to the PDC-blocking by anti-BDCA2 treatment completely reverses the inhibition of T cell expansion (Fig. 3b) and induction of psoriasis development (Fig. 3c, d), confirming that the development of psoriasis is mediated by IFN-α production by PDC. These data prove that IFN-α is the responsible type IFN for psoriasis development.
Specific blockade of IFN-α blocks psoriasis while leaving IFN-β signalling intact for a potential antiviral immune response.
Blocking agents refer to any DNA, RNA (si RNA, antisense molecules), peptide, protein (including fusion protein), antibody or small molecules interfering with type I IFN signalling and function and/or type I IFN production by PDCs in inflammatory diseases. In particular such blocking agents are (i) humanized or human anti-IFN-α whole antibodies or antibody fragments (Fab or scFv), antagonizing secreted IFN-α, (ii) short interfering (si) RNA or antisense oligonucleotides inhibiting IFN-α production, (iii) anti-IFN-α/β-receptor antibodies, mutant type I IFN/Fc fusion proteins, type I IFN receptor fusion proteins, or small molecules interfering with type I IFN signalling.
One aspect of the invention relates to a method of treating psoriasis comprising administering an anti-IFN-α antibody or antibody fragment in a quantity effective against psoriasis to a mammal in need thereof, for example to a human requiring such treatment. The treatment may be for prophylactic or therapeutic purposes. For the administration, the anti-IFN-α antibody is preferably in the form of a pharmaceutical preparation comprising the anti-IFN-α antibody and optionally a pharmaceutically acceptable carrier and optionally adjuvants. The anti-IFN-α antibody is used in an amount effective against psoriasis. The dosage of the active ingredient depends upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, the mode of administration, and whether the administration is for prophylactic or therapeutic purposes. In the case of an individual having a bodyweight of about 70 kg the daily dose administered is from approximately 1 mg to approximately 500 mg, preferably from approximately 10 mg to approximately 100 mg, of an anti-IFN-α antibody.
Administering other blocking agents referred to above is also included in the invention, in particular administering pharmaceutical preparations comprising short interfering (si) RNA or antisense oligonucleotides inhibiting IFN-α production, or anti-IFN-α/β-receptor antibodies, mutant type I IFN/Fc fusion proteins, type I IFN receptor fusion proteins or small molecules interfering with type I IFN signalling. These compounds are likewise used in an amount effective against psoriasis. The dosage is chosen by the practitioner based on the particular compound to be administrated and the individual pharmacokinetic data, and also on the species, its age, weight, and individual condition and the mode of administration.
Pharmaceutical compositions for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, are especially preferred. The pharmaceutical compositions comprise from approximately 1% to approximately 95% active ingredient, preferably from approximately 20% to approximately 90% active ingredient. For parenteral administration preference is given to the use of suspensions or dispersions of the anti-IFN-α antibody or other type I IFN blocking agent mentioned above, especially in isotonic aqueous solutions, which, for example, can be made up shortly before use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-increasing agents, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known perse, for example by means of conventional dissolving and lyophilizing processes.
An antibody useful in the invention is prepared by standard methods. Humanized antibodies and antibody fragments are obtained by recombinant technologies as previously described [reviewed by Dall'Acqua et al., Curr Op Struct Biol 1988, 8: 443-50]. Alternatively, entirely human antibodies can be obtained using either phage display technologies [reviewed by Winter et al., Annu Rev Immunol 1994, 12: 433-55] or transgenic "human" mice with partial human heavy and light chain loci inserted into their genomes [reviewed by Brϋggeman et al., Curr Op Biotechnol 1997, 8: 503-8]. Preparation of si RNA or antisense oligonucleotides likewise uses standard technology.
An anti-IFN-α antibody or other type I IFN blocking agent mentioned above can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations of a blocking agent of the invention and one or more other therapeutic agents known in the treatment of psoriasis, the administration being staggered or given independently of one another, or being in the form of a fixed combination.
Combination partners considered are topical corticosteroids, UV light, retinoids, methotrexate, other biologies targeting the altered immune system in psoriasis or derivatives of vitamin D3.
The following Examples serve to illustrate the invention without limiting the invention in its scope.
Examples Real time quantitative PCR. Total RNA from homogenized skin specimens is extracted and reverse transcribed as previously described [Boyman et al., J Exp Med 2004, 199: 731-736]. Complementary DNA is quantitatively analyzed for the expression of IFN-α and IRF-7 transcripts by real time PCR, using primers designed against most human IFN-α sequences (purchased from Applied Biosystems, Foster City, CA) and against human IRF-7 (left, TCCCCACGCTATACCATCTACCT-3'; right, ACAGCCAGGGTTCCAGCTT- 3'). 18S ribosomal RNA is used for normalisation. In the humanized mouse model IFN-α quantification is done by using a primer kit recognizing most human IFN-α genes and which does not recognize its mouse counterpart (purchased from Search-LC, Heidelberg, Germany). Human GAPDH mRNA levels are quantified using human-specific primers (left, ATTGCCCTCAACGACCACTTTG-3'; right, TTGATGGTACATGAAAGGTGAGG-3') and used for normalization.
Animals, and Transplantation Procedure. AGR129 mice, deficient in type I (A) and type Il (G) IFN receptors in addition to being RAG-2"'", are kept pathogen free throughout the study. Keratomes of symptomless pre-psoriatic skin are transplanted to the back of mice using an absorbable tissue seal, as previously described [Boyman et al., loc. cit.]. 35 days after engraftment transplanted skin is removed and snap frozen for histological or mRNA expression analysis. CD3+ T cell counts, acanthosis and papillomatosis index are determined histologically as previously published [Boyman et al., loc. cit.]. CD3+ T cell values represent the mean cell count of three random fields assessed by a 400-fold magnification by two independent investigators. The indicated papillomatosis and acanthosis values represent the mean of 10 random areas of each sample.
Neutralization Studies. Dosage and schedule of antibody administration are deduced based on previous data with anti-human monoclonal antibodies against other cell surface molecules, and administered as follows: (i) intravenous injection of 30 μg neutralizing anti- human IFN-α/β Receptor Chain 2 (CD118) mAb (Clone MMHAR-2, purchased from PBL Biomedical Labortories) twice weekly for 35 days, starting at day 0 after transplantation; (ii) intravenous injection of 30 μg anti-BDCA-2 mAb (Miltenyi Biotech) twice weekly for 35 days, starting at day 0 after transplantation. For IFN-α reconstitution experiments, 30'0OO IU recombinant human IFN-α2a (Roferon®A, Roche Pharma AG1 Reinach, Switzerland) are administered subcutaneously 3 times a week for 35 days. Dosage corresponds to the therapeutic dose of 8 Mio IU used in humans, and is deduced by an allometric approach as previously described [Boyman et al., loc. cit.].

Claims

Claims
1. Use of a type I interferon blocking agent for the preparation of a medicament for the prevention and treatment of psoriasis.
2. Use according to claim 1 wherein the type I interferon blocking agent is a type I interferon antagonist.
3. Use according to claim 2 wherein the type I interferon antagonist is an IFN-α antagonist.
4. Use according to claim 3 wherein the IFN-α antagonist is an anti-IFN-α antibody or antibody fragment.
5. Use according to claim 1 wherein the type I interferon blocking agent is a type I interferon receptor fusion protein
6. Use according to claim 1 wherein the type I interferon blocking agent is a short interfering (si) RNA or an antisense oligonucleotide inhibiting IFN-α production.
7. Use according to claim 1 wherein the type I interferon blocking agent is a type I interferon receptor antagonist.
8. Use according to claim 7 wherein the type I interferon receptor antagonist is an anti-IFN-α/β-receptor antibody, mutant type I IFN/Fc fusion protein or small molecule specifically interfering with type I IFN signalling.
9. Use according to claim 7 wherein the type I interferon receptor antagonist is an anti- IFN-α/β-receptor antibody or antibody fragment.
10. Use according to claim 4 or 9 wherein the antibody is a humanized antibody.
11. A method of prevention and treatment of psoriasis using a type I interferon blocking agent. SEQUENCE LISTING
<110> Nestle, Frank o. Gilliet, Michel
<120> Type I interferon blocking agents for prevention and treatment of psoriasis
<130> UZ-06/167
<160> 4
<170> Patentln version 3.3
<210> 1
<211> 23
<212> DNA
<213> artificial
<22O>
<223> pri mer for IRF-7 , l eft
<400> 1 tccccacgct ataccatcta cct 23
<210> 2
<211> 19
<212> DNA
<213> artificial
<22O>
<223> primer for IRF-7, right
<400> 2 acagccaggg ttccagctt 19
<210> 3
<211> 22
<212> DNA
<213> arti fi ci al
<220>
<223> primer for GAPDH, left
<400> 3 attgccctca acgaccactt tg 22
<210> 4
<211> 23
<212> DNA
<213> artificial
<22O>
<223> primer for GAPDH, right
<400> 4 ttgatggtac atgaaaggtg agg 23
PCT/CH2005/000566 2004-10-07 2005-09-30 Type i interferon blocking agents for prevention and treatment of psoriasis WO2006037247A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2005291741A AU2005291741B2 (en) 2004-10-07 2005-09-30 Type I interferon blocking agents for prevention and treatment of psoriasis
CA002582471A CA2582471A1 (en) 2004-10-07 2005-09-30 Type i interferon blocking agents for prevention and treatment of psoriasis
JP2007534986A JP2008515819A (en) 2004-10-07 2005-09-30 Type I interferon blocking agent for prevention and treatment of psoriasis
MX2007003809A MX2007003809A (en) 2004-10-07 2005-09-30 Type i interferon blocking agents for prevention and treatment of psoriasis.
BRPI0516470-2A BRPI0516470A (en) 2004-10-07 2005-09-30 use of a type i interferon blocking agent, and method of prevention and treatment of psoriasis
NZ554065A NZ554065A (en) 2004-10-07 2005-09-30 Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis
EP05786466A EP1796722A1 (en) 2004-10-07 2005-09-30 Type i interferon blocking agents for prevention and treatment of psoriasis
US11/664,869 US20090155286A1 (en) 2004-10-07 2005-09-30 Type I interferon blocking agents for prevention and treatment of psoriasis
IL182087A IL182087A0 (en) 2004-10-07 2007-03-21 Type i interferon blocking agents for prevention and treatment of psoriasis
NO20072024A NO20072024L (en) 2004-10-07 2007-04-20 Type 1 blockers for the prevention and treatment of psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405628.1 2004-10-07
EP04405628 2004-10-07

Publications (1)

Publication Number Publication Date
WO2006037247A1 true WO2006037247A1 (en) 2006-04-13

Family

ID=35593663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2005/000566 WO2006037247A1 (en) 2004-10-07 2005-09-30 Type i interferon blocking agents for prevention and treatment of psoriasis

Country Status (15)

Country Link
US (1) US20090155286A1 (en)
EP (2) EP1796722A1 (en)
JP (1) JP2008515819A (en)
KR (1) KR20070083809A (en)
CN (1) CN101056654A (en)
AU (1) AU2005291741B2 (en)
BR (1) BRPI0516470A (en)
CA (1) CA2582471A1 (en)
IL (1) IL182087A0 (en)
MX (1) MX2007003809A (en)
NO (1) NO20072024L (en)
NZ (1) NZ554065A (en)
RU (2) RU2007116988A (en)
WO (1) WO2006037247A1 (en)
ZA (1) ZA200702794B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544357B2 (en) 2001-01-09 2009-06-09 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US8080638B2 (en) 2005-02-10 2011-12-20 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US8163885B2 (en) 2008-05-07 2012-04-24 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
FR2968561A1 (en) * 2010-12-13 2012-06-15 Lfb Biotechnologies USE OF ANTIBODY AGAINST A MEMBRANE PROTEIN

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2623978A1 (en) * 2012-02-03 2013-08-07 Charité - Universitätsmedizin Berlin CD8+ T-cell subsets as markers for prediction of delayed fracture healing
CN103319608B (en) * 2013-07-01 2014-08-27 江苏众红生物工程创药研究院有限公司 Pig IFNalpha1-Fc fusion protein as well as encoding gene and expression method thereof
CN106029874B (en) 2013-12-16 2020-09-15 北卡罗来纳-查佩尔山大学 Depletion of plasmacytoid dendritic cells
EP3088519A4 (en) * 2013-12-24 2017-09-13 Astellas Pharma Inc. Novel anti-human bdca-2 antibody
HRP20240603T1 (en) 2016-07-01 2024-07-19 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CN111315767A (en) 2017-08-22 2020-06-19 萨纳生物有限责任公司 Soluble interferon receptors and uses thereof
CN112135623B (en) * 2018-06-01 2024-03-26 Ilc医疗有限公司 Compositions and methods relating to the treatment of disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
WO1998028001A1 (en) * 1996-12-23 1998-07-02 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including aids
WO2000024417A1 (en) * 1998-10-23 2000-05-04 Monash University A method of regulation
WO2001036487A2 (en) * 1999-11-15 2001-05-25 Miltenyi Biotec Inc. Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2001054721A1 (en) * 2000-01-25 2001-08-02 Pharma Pacific Pty Ltd Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
US20040067888A1 (en) * 2000-01-25 2004-04-08 Tovey Michael Gerard Therapeutic peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4605394A (en) * 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
DE3211263A1 (en) * 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo HUMAN INTERFERON RELATED PEPTIDES, ANTIGENS AND ANTIBODIES, AND METHOD FOR THE PRODUCTION THEREOF
WO1984003106A1 (en) * 1983-02-04 1984-08-16 Wadley Inst Of Molecular Medic Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
FR2560212B1 (en) * 1984-02-24 1989-12-29 Unicet MONOCLONAL ANTIBODIES AGAINST INTERFERON A2 AND HYBRIDOMAS PRODUCING SUCH ANTIBODIES
DE19919149A1 (en) 1999-04-27 2000-11-16 Wieser Raimund J Interferon alpha-2 derived peptide homodimers and peptide heterodimers
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
WO2002067760A2 (en) * 2001-01-09 2002-09-06 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1578397B1 (en) * 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
PT1711207E (en) * 2003-12-10 2013-02-13 Medarex Inc Interferon alpha antibodies and their uses
KR101363120B1 (en) * 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 Anti-Interferon Alpha Monoclonal Antibodies and Methods for Use
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
WO1998028001A1 (en) * 1996-12-23 1998-07-02 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including aids
WO2000024417A1 (en) * 1998-10-23 2000-05-04 Monash University A method of regulation
WO2001036487A2 (en) * 1999-11-15 2001-05-25 Miltenyi Biotec Inc. Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2001054721A1 (en) * 2000-01-25 2001-08-02 Pharma Pacific Pty Ltd Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
US20030147889A1 (en) * 2000-01-25 2003-08-07 Tovey Michael Gerard Antagonist of th-1 immunerresponse inducing cytokine for the treatment of autoimmune diseases
US20040067888A1 (en) * 2000-01-25 2004-04-08 Tovey Michael Gerard Therapeutic peptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NESTLE F.O.: "Plasmocytoid predendritic cells initiate psoriasis through interferon-alpha production", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 202, no. 1, 4 July 2005 (2005-07-04), pages 135 - 143, XP002364226 *
SCHMID P ET AL: "THE TYPE I INTERFERON SYSTEM IS LOCALLY ACTIVATED IN PSORIATIC LESIONS", JOURNAL OF INTERFERON RESEARCH, MARY ANN LIEBERT, INC., NEW YORK, NY, US, vol. 14, no. 5, October 1994 (1994-10-01), pages 229 - 234, XP008017805, ISSN: 0197-8357 *
VAN DER FITS L. ET AL.: "In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 1, January 2004 (2004-01-01), pages 51 - 60, XP002364225 *
WOLLENBERG ET AL.: "Plasmocytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 19, no. 5, November 2002 (2002-11-01), pages 1096 - 1102, XP002364224 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544357B2 (en) 2001-01-09 2009-06-09 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US8080638B2 (en) 2005-02-10 2011-12-20 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US8333965B2 (en) 2005-02-10 2012-12-18 Baylor Research Institute Anti-inteferon alpha monoclonal antibodies and methods for use
US8163885B2 (en) 2008-05-07 2012-04-24 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
US8361463B2 (en) 2008-05-07 2013-01-29 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
US8658771B2 (en) 2008-05-07 2014-02-25 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
FR2968561A1 (en) * 2010-12-13 2012-06-15 Lfb Biotechnologies USE OF ANTIBODY AGAINST A MEMBRANE PROTEIN
WO2012080642A1 (en) 2010-12-13 2012-06-21 Lfb Biotechnologies Use of an antibody directed against a membrane protein
EP3190127A1 (en) 2010-12-13 2017-07-12 Laboratoire Français du Fractionnement et des Biotechnologies Use of an antibody directed against bdca-2 for the treatment of autoimmune or inflammatory disorders
EP3438129A1 (en) * 2010-12-13 2019-02-06 Laboratoire Français du Fractionnement et des Biotechnologies Composition of monoclonal antibodies directed against bdca-2

Also Published As

Publication number Publication date
IL182087A0 (en) 2007-07-24
AU2005291741A1 (en) 2006-04-13
CN101056654A (en) 2007-10-17
EP2286835A1 (en) 2011-02-23
KR20070083809A (en) 2007-08-24
RU2010146161A (en) 2012-05-20
AU2005291741B2 (en) 2011-11-24
NZ554065A (en) 2010-12-24
CA2582471A1 (en) 2006-04-13
BRPI0516470A (en) 2008-09-09
US20090155286A1 (en) 2009-06-18
MX2007003809A (en) 2007-09-12
ZA200702794B (en) 2008-06-25
EP1796722A1 (en) 2007-06-20
JP2008515819A (en) 2008-05-15
RU2007116988A (en) 2008-11-20
NO20072024L (en) 2007-04-26

Similar Documents

Publication Publication Date Title
AU2005291741B2 (en) Type I interferon blocking agents for prevention and treatment of psoriasis
Joosten et al. Anticytokine treatment of established type II collagen–induced arthritis in DBA/1 mice: a comparative study using anti‐TNFα, anti–IL‐1α/β, and IL‐1Ra
CN118141914A (en) Methods for preventing or treating allergy by administering IL-4R antagonists
EP1137766B1 (en) Use of il-12 antibodies to treat psoriasis
KR20190014117A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
JP2015524793A (en) Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3, and anti-CXCR5 agonists for inflammation inhibition
JP2009543579A (en) WSX-1 / p28 as a target for anti-inflammatory response
Helsen et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta, and IL-1Ra
DK2219452T3 (en) PROCESSES FOR THE TREATMENT OF scleroderma.
JP6379331B2 (en) Compounds for treating remyelination blockade in HERV-W envelope protein expression related diseases
US10640768B2 (en) Method of treating pain with an antibody against netrin-4, UNC5B or neogenin
US20030211103A1 (en) Use of primate IFN-gamma binding molecules
US9221904B2 (en) Treatment of osteoarthritis using IL-20 antagonists
EP1423138B1 (en) Use of il-18 inhibitors in hypersensitivity disorders
KR20210042138A (en) How to treat psoriasis
JP2004315381A (en) THERAPEUTIC DRUG FOR IMMUNOLOGICAL DISEASE USING STIMULATION OF NATURAL KILLER T CELL BY INTERLEUKIN 18, THERAPEUTIC KIT, AND METHOD FOR CONTROLLING IgE PRODUCTION
CN114980901A (en) Methods of treating chronic fatigue syndrome using inhibitors or cytotoxic agents directed against plasma cells
TW202019482A (en) Agent for treatment or prevention of htlv-1-associated myelopathy (ham), and ham treatment method
US20170348389A1 (en) Treating liver diseases with interleukin 24
Schopf et al. Alterations of intralesional and lymph node gene expression and cellular composition induced by IL‐12 administration during leishmaniasis
WO2010046474A2 (en) Chemoattractants inhibitors
KR20200039028A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 182087

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 554065

Country of ref document: NZ

Ref document number: 2005291741

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003809

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007/02794

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 12007500761

Country of ref document: PH

Ref document number: 2582471

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200580033920.2

Country of ref document: CN

Ref document number: 2007534986

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005291741

Country of ref document: AU

Date of ref document: 20050930

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005291741

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 07040127

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 3095/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005786466

Country of ref document: EP

Ref document number: 1020077009475

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007116988

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005786466

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11664869

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0516470

Country of ref document: BR